BMEA

Biomea Fusion (BMEA)

Biomea Fusion Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:BMEA

1 2 3 4 5 6 7 8 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2025/01/13	23:00	GlobeNewswire Inc.	Biomea Fusion to Become a Diabetes & Obesity Medicines Company	NASDAQ:BMEA	Biomea Fusion Inc
2025/01/07	23:00	GlobeNewswire Inc.	Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study	NASDAQ:BMEA	Biomea Fusion Inc
2025/01/07	06:57	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:BMEA	Biomea Fusion Inc
2025/01/06	21:00	GlobeNewswire Inc.	Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference	NASDAQ:BMEA	Biomea Fusion Inc
2024/12/21	05:06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BMEA	Biomea Fusion Inc
2024/12/17	22:10	GlobeNewswire Inc.	Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes	NASDAQ:BMEA	Biomea Fusion Inc
2024/12/17	08:15	GlobeNewswire Inc.	Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)	NASDAQ:BMEA	Biomea Fusion Inc
2024/12/13	07:02	GlobeNewswire Inc.	Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)	NASDAQ:BMEA	Biomea Fusion Inc
2024/12/10	06:01	GlobeNewswire Inc.	Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia	NASDAQ:BMEA	Biomea Fusion Inc
2024/12/06	22:00	GlobeNewswire Inc.	Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia	NASDAQ:BMEA	Biomea Fusion Inc
2024/12/03	06:05	GlobeNewswire Inc.	Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:BMEA	Biomea Fusion Inc
2024/11/18	22:00	GlobeNewswire Inc.	Late-Breaker Oral Presentation Showing New Analysis from the Escalation Portion of COVALENT-111 Presented at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)	NASDAQ:BMEA	Biomea Fusion Inc
2024/11/02	05:05	GlobeNewswire Inc.	Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:BMEA	Biomea Fusion Inc
2024/10/31	19:07	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BMEA	Biomea Fusion Inc
2024/10/31	05:00	GlobeNewswire Inc.	Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate	NASDAQ:BMEA	Biomea Fusion Inc
2024/10/30	06:19	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:BMEA	Biomea Fusion Inc
2024/10/30	06:06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BMEA	Biomea Fusion Inc
2024/10/30	05:46	GlobeNewswire Inc.	Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights	NASDAQ:BMEA	Biomea Fusion Inc
2024/10/21	22:00	GlobeNewswire Inc.	Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219	NASDAQ:BMEA	Biomea Fusion Inc
2024/10/16	05:05	GlobeNewswire Inc.	Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1 R	NASDAQ:BMEA	Biomea Fusion Inc
2024/10/07	22:00	GlobeNewswire Inc.	Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)	NASDAQ:BMEA	Biomea Fusion Inc
2024/10/02	05:30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BMEA	Biomea Fusion Inc
2024/10/01	22:00	GlobeNewswire Inc.	Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts	NASDAQ:BMEA	Biomea Fusion Inc
2024/09/28	05:02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BMEA	Biomea Fusion Inc
2024/09/27	03:00	GlobeNewswire Inc.	FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials	NASDAQ:BMEA	Biomea Fusion Inc
2024/08/02	05:05	GlobeNewswire Inc.	Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:BMEA	Biomea Fusion Inc
2024/08/01	05:14	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:BMEA	Biomea Fusion Inc
2024/08/01	05:13	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BMEA	Biomea Fusion Inc
2024/08/01	05:05	GlobeNewswire Inc.	Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate Highlights	NASDAQ:BMEA	Biomea Fusion Inc
2024/06/14	05:30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BMEA	Biomea Fusion Inc